Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
TNYA Stock Chart & Stats
$1.33
-$0.05(-3.69%)
At close: 4:00 PM EST
$1.33
-$0.05(-3.69%)
Day’s Range― - ―
52-Week Range$0.36 - $2.35
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.00M
Market Cap
$142.89M
Enterprise Value$60.38M
Total Cash (Recent Filing)$56.31M
Total Debt (Recent Filing)$11.53M
Price to Earnings (P/E)―
Beta2.73
Next Earnings
Mar 24, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding216,505,890
10 Day Avg. Volume2,873,734
30 Day Avg. Volume4,003,933
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.29
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$3.00Price Target Upside125.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyInterim TN-401 data showing early functional benefit and meaningful reductions in arrhythmia burden indicate clinical proof-of-concept that could increase investor confidence in the program.
Financial RunwayA strengthened cash position provides runway to support ongoing clinical execution and regulatory interactions, reducing near-term financing risk for the development plan.
Safety ProfileTN-401's tolerable safety profile with no dose-limiting toxicities or major cardiac adverse events distinguishes the program and supports continued patient enrollment and development.
Bears Say
Clinical VariabilityHeterogeneous patient responses, including instances with no measurable expression and no clinical improvement, raise uncertainty about reproducibility and increase program risk.
Competitive DifferentiationReported protein increases appear smaller than some competitor programs, which could limit competitive differentiation unless higher-dose or longer-term data demonstrate clear improvements.
Regulatory OverhangFDA-imposed clinical holds requiring standardized patient monitoring and immunosuppression protocols create a regulatory overhang that could complicate trial operations and enrollment.
Tenaya Therapeutics News
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.36 and its highest was $2.35 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $142.89M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 33 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.148 by $0.028.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 216,505,890 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.148. Following the earnings report the stock price went up 11.719%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenaya Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.00 (125.56% Upside)
$3.00 (125.56% Upside)
Hedge Fund Trend
Decreased
By 5.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.73%
12-Months-Change
Fundamentals
Return on Equity
-96.44%
Trailing 12-Months
Asset Growth
-25.32%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
TNYA Stock 12 Month Forecast
Average Price Target
$3.00
▲(125.56% Upside)
Technical Analysis
Galectin Therapeutics
―
Abeona Therapeutics
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Candel Therapeutics
―
Ownership Overview
54.87% Insiders
2.54% Mutual Funds
0.36% Other Institutional Investors
37.95% Public Companies and Individual Investors